Login to Your Account

Lilly psoriasis drug wins FDA approval, joins crowded space

By Michael Fitzhugh
Staff Writer

Wednesday, March 23, 2016

Eli Lilly and Co. has gained FDA approval for Taltz (ixekizumab), a new drug intended to help clear the skin of adults with moderate to severe cases of plaque psoriasis, a patient population with a growing number of therapies from which to choose.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription